CompletedNot Applicable

The Orkdal Model. Collaboration Between Specialist and Community Care Within Palliative Cancer Care

Norway969 participantsStarted 2014-11

Plain-language summary

The overall aim of this project is to deliver better health care services through improved coordination of cancer care within specialist care (at the local hospital Orkdal Hospital) and community care (13 municipalities in the Orkdal region, Norway), and between these two levels in the health care system. "The Orkdal model" is developed and will be implemented and evaluated within cancer care. Cancer patients living in one of the 12 municipalities participating in the formal collaboration "Samhandlingsenheten i Orkdalsregionen" (SIO), or the municipality of Oppdal, having metastatic and/or loco-regional disease will be included in the study. Carers and health care providers will be included as well. Results from this project will be transferable to other parts of Norway and/or to other countries as well as to patients with other diagnoses causing complex conditions, such as chronic heart-, lung- and neurological disease.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria (Patients): * Advanced loco-regional disease and/or metastatic cancer disease * For the intervention group in the Orkdal region: Inhabitant of one of the following thirteen districts: Surnadal, Halsa, Rindal, Hemne, Orkdal, Frøya, Hitra, Snillfjord, Agdenes, Meldal, Rennebu, Skaun, and Oppdal * For the intervention group in the Romsdal region: Inhabitiant of one of the following nine districts: Aukra, Molde, Eide, Vestnes, Sunndal, Fræna, Midsund, Nesset, Rauma * Acceptance of participation, based on information about the study and that participation is voluntary. Documented by a signed consent form. * Able to comply with the study procedures * Able to read and write Norwegian Inclusion criteria (Carers) (a carer a person identified as such by the patient) * the patient is eligible for the study * the patient has given his or her consent to allow the study nurse to approach the carer to participate in the study * the patient has identified the carer to be approached * acceptance of participation, based on information about the study and that participation is voluntary. Documented by a signed consent form. Inclusion Criteria (Health care providers) * has accepted to participate in the study * Acceptance of participation, based on information about the study and that participation is voluntary. Documented by an electronically signed consent form. Exclusion Criteria (Patients): * Receiving anti-cancer treatment with curative intent Exclusion Criteria (…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

proportion of patient's time spent at home the last 3 months of life

Timeframe: 3 years

carers' health related quality of life (HRQOL) 6 months after patient's death

Timeframe: 3 years

Trial details

NCT IDNCT02170168

SponsorSt. Olavs Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-03-31

View on ClinicalTrials.gov More Neoplasms trials